Spike Protein News and Research

RSS

Research may provide clues to how viral infections contribute to neurodegeneration

Some viral diseases could possibly contribute to neurodegeneration. DZNE researchers report this in the scientific journal "Nature Communications".

19 Oct 2021

Phase 2 trial shows COVID-19 recombinant protein vaccine elicits promising immunogenicity responses

Researchers performed a large-scale, double-blind, placebo-controlled phase two trial to assess the efficacy, safety, and immune response elicited from vaccination with MVC-COV1901.

19 Oct 2021

Structural mechanism of anti-SARS-CoV-2 neutralizing antibodies that target separate spike epitopes

Researchers from the Washington University School Of Medicine have identified how a subset of variants of concern can escape neutralization by two neutralizing antibodies.

19 Oct 2021

SARS-CoV-2 antibodies detected in breast milk of vaccinated mothers

Now, a new medRxiv* preprint study finds mothers vaccinated either one of the messenger RNA (mRNA) vaccines transferred neutralizing antibodies and cytokines, including interferon-gamma (IFNγ), to a breastfeeding child. Additionally, the humoral response in breastmilk was effective in neutralizing four variants of concern.

18 Oct 2021

Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine

Researchers from Singapore conducted a study to assess the spike protein-specific humoral and cellular immunity in Ad26.COV2.S vaccinated individuals either primed with Ad26.COV2.S only, or boosted with a homologous or heterologous second dose.

18 Oct 2021

How can framing COVID-19 vaccine side-effects affect an individual's willingness to be vaccinated?

Researchers from the University of Munich have investigated how framing vaccine side-effects can affect an individual's willingness to be vaccinated.

18 Oct 2021

Study assesses T-cell responses directed against highly conserved regions of SARS-CoV-2

The study aimed to assess whether highly conserved regions within coronaviruses harbor CD8+ T-cell epitopes, capable of being cross-recognized between different coronaviruses.

18 Oct 2021

Study provides the most detailed analysis of England's SARS-CoV-2 genomic surveillance information

The Covid-19 crisis that gripped the UK between September 2020 and June 2021 can be thought of as a series of overlapping epidemics, rather than a single event, say researchers at the Wellcome Sanger Institute, EMBL's European Bioinformatics Institute (EMBL-EBI) and their collaborators.

18 Oct 2021

Serologic testing algorithm to detect disparities in SARS-CoV-2 infection prevalence and vaccination uptake

A new study recently published on the medRxiv* preprint server demonstrates the use of a serological testing algorithm for identifying disparities in infection rates and vaccine uptake amongst the study population to enable public health interventions.

17 Oct 2021

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

A group of researchers from the United States discovered that the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce the formation of highly inflammatory blood clots amenable to neutralization by a fibrin-targeting monoclonal antibody – opening the door for a completely new strategy to reduce thrombotic inflammation in coronavirus disease 2019 (COVID-19).

17 Oct 2021

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

The efficacy and safety of a DNA-based vaccine are investigated, finding that the unique vaccine imparts a robust and long-lasting immunogenic response.

15 Oct 2021

Phase 2 study shows safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine

The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.

15 Oct 2021

Increased transmission in open spike conformations of SARS-CoV-2 variants

Researchers from Yale University and the University of Texas have collaborated to investigate mutations in some VOCs.

14 Oct 2021

Mutation of cysteine residues in NRP1 reduces SARS-CoV-2 spike protein entry into cells

Researchers have been investigating altered protein conformations in variants of concern to provide further insight for future therapies against COVID-19.

14 Oct 2021

Assay for the sensitive and specific identification of SARS-CoV-2 Delta variant

Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).

14 Oct 2021

COVID-19 booster for immunosuppressed patients with inflammatory bowel disease

Researchers have published correspondence detailing the reasoning behind providing a third booster dose to patients with inflammatory bowel disease that have been treated with drugs that can reduce the response to the COVID-19 vaccines.

14 Oct 2021

Small portion of COVID-19 patients infectious long-term

In late December 2019, a novel pneumonia-like lung infection was reported in the Chinese province of Hubei. This, in turn, led to the ongoing coronavirus disease-19 (COVID-19) pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to SARS (Severe Acute Respiratory Syndrome) and MERS (the Middle East Respiratory Syndrome Coronavirus).

13 Oct 2021

Anti-rheumatic drug as a potential candidate for treating COVID-19

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces inflammatory cytokine storms. But an FDA-approved anti-rheumatic drug, Auranofin, used to treat autoimmune and infectious diseases, may also help serve as an antiviral treatment for COVID-19 infection.

13 Oct 2021

COVID-19 vaccination induces transient increase in cellular and antibody responses to S1 antigenic sequence

Scientists have characterized T-cell, B-cell, and IgG responses to S antigenic sequences to evaluate vaccine effectiveness.

13 Oct 2021

How long does natural immunity produced by SARS-CoV-2 infection last?

A new study posted to the bioRxiv* preprint server followed the adaptive immune response in convalescent patients from Swedish and Italian cohorts—which had earlier shown long-lasting adaptive immune responses to the G614 strain—for 15 months. Here, specific antibody levels and neutralizing antibody titers were tested against variants of concern (VOCs).

12 Oct 2021

Spike Protein News and Research

Research may provide clues to how viral infections contribute to neurodegeneration

Phase 2 trial shows COVID-19 recombinant protein vaccine elicits promising immunogenicity responses

Structural mechanism of anti-SARS-CoV-2 neutralizing antibodies that target separate spike epitopes

SARS-CoV-2 antibodies detected in breast milk of vaccinated mothers

Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine

How can framing COVID-19 vaccine side-effects affect an individual's willingness to be vaccinated?

Study assesses T-cell responses directed against highly conserved regions of SARS-CoV-2

Study provides the most detailed analysis of England's SARS-CoV-2 genomic surveillance information

Serologic testing algorithm to detect disparities in SARS-CoV-2 infection prevalence and vaccination uptake

Fibrin immunotherapy may resolve blood clotting induced by SARS-CoV-2

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

Phase 2 study shows safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine

Increased transmission in open spike conformations of SARS-CoV-2 variants

Mutation of cysteine residues in NRP1 reduces SARS-CoV-2 spike protein entry into cells

Assay for the sensitive and specific identification of SARS-CoV-2 Delta variant

COVID-19 booster for immunosuppressed patients with inflammatory bowel disease

Small portion of COVID-19 patients infectious long-term

Anti-rheumatic drug as a potential candidate for treating COVID-19

COVID-19 vaccination induces transient increase in cellular and antibody responses to S1 antigenic sequence

How long does natural immunity produced by SARS-CoV-2 infection last?

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News